ArticlemBio2019
Targeting Multidrug-Resistant
Abstract read
In one paragraph
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Resistance ofPathogens (Basel, Switzerland) · 2025Pooled it
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.Antimicrobial agents and chemotherapy · 2025Trial
- Characterization ofAntimicrobial agents and chemotherapy · 2024Trial
- A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects.Clinical and translational science · 2021Trial
- Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.Antimicrobial agents and chemotherapy · 2020Trial
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.Antimicrobial agents and chemotherapy · 2020Trial
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Disarming carbapenemase-producingAntimicrobial agents and chemotherapy · 2026Article
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics.MicrobiologyOpen · 2026Review
- In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes.The Journal of antimicrobial chemotherapy · 2026Article
- Microbiological eradication of XDRFrontiers in medicine · 2026Article
- Unraveling the mechanisms behind the enhanced efficacy of β-lactam-based sideromycins.Communications biology · 2025Article
- Article
- Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators againstAntimicrobial agents and chemotherapy · 2025Article
- Review
- ComparativeJAC-antimicrobial resistance · 2025Article
- Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.Journal of virology · 2025Article
- A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) ofAntimicrobial agents and chemotherapy · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Melissa D Barnes *Louis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Vijay Kumar *Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-2741-8891
Christopher R BethelLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Samir H MoussaEntasis Therapeutics, Waltham, Massachusetts, USA.
John O'DonnellEntasis Therapeutics, Waltham, Massachusetts, USA.
Joseph D RutterLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Caryn E GoodDepartment of Pathology, University Hospitals, Cleveland Medical Center, Cleveland, Ohio, USA.
Kristine M HujerLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Andrea M HujerLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Steve H MarshallLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
Barry N KreiswirthPublic Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
Sandra S RichterCleveland Clinic Foundation, Cleveland, Ohio, USA.
Philip N RatherDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Michael R JacobsDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Krisztina M Papp-WallaceLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.ORCID 0000-0002-9976-7898
Focco van den AkkerDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA fxv5@case.edu robert.bonomo@va.gov.
Robert A BonomoLouis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA fxv5@case.edu robert.bonomo@va.gov.
Funding
The molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MDissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complexR01AI141805 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI BARRY Neal KREISWIRTH · 2019 to 2026
$5.1MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MTargeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–BLRD Research Career Scientist Award ApplicationIK6BX004470 · VA · VETERANS HEALTH ADMINISTRATION · PI Philip N. Rather · 2019 to 2026
–BLRD VA I01 BX001725BLRD VA I01 BX001974BLRD VA I01 BX002872BLRD VA IK6 BX004470NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI090155NIAID NIH HHS R01 AI100560
Abstract
Multidrug-resistant (MDR)
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCrystallography, X-RayDisease Models, AnimalMiceProtein BindingProtein ConformationSulbactamTreatment OutcomeAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesdurlobactamSulbactamAcinetobacterbeta-lactamasesbeta-lactamsDBOdiazabicyclooctanonediazabicyclooctenoneETX2514sulbactamβ-lactamase inhibitor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.